Subscribe to RSS - ResMed

ResMed

German court sides with ResMed

 - 
10/13/2017

SAN DIEGO – ResMed says that a Munich District Court has decided that its AirSense 10 and AirCurve 10 CPAP devices and its Lumis ventilators, along with their humidifiers, do not infringe a Fisher & Paykel short-term patent, StreetInsider reports.

ResMed provides update on lawsuits in four countries

 - 
10/06/2017

SAN DIEGO – ResMed says a German court has stayed infringement proceedings against Fisher & Paykel to allow ResMed to defend the validity of its patents in the European Patent Office.

Lawsuit update: ResMed vs. Fisher & Paykel

 - 
10/03/2017

SAN DIEGO – A German court has suspended ResMed’s intellectual property proceedings against Fisher & Paykel Healthcare, according to news reports.

Short takes: Philips, 3B Medical, Peter Farrell

 - 
09/14/2017

Frost & Sullivan has awarded Philips with the 2017 North American Home Ventilation Product Leadership Award for its Trilogy line of homecare ventilators.

Telemonitoring improves CPAP adherence, study finds

 - 
09/12/2017

SAN DIEGO – The use of CPAP telemonitoring with automated feedback messaging improved 90-day adherence in patients with obstructive sleep apnea, according to a ResMed-supported

ResMed sets high expectations for mask sales

Company says it’s ready to ‘unleash’ sales force
 - 
08/04/2017

SAN DIEGO – ResMed expects to see a nice bump in mask sales in the first quarter of its fiscal year 2018, now that it has manufacturing “sufficiently ramped up” for two new masks, the N20 and F20, says CEO Mick Farrell.

ResMed closes fiscal year with 12% increase in revenues, 3% decrease in net income

 - 
08/02/2017

SAN DIEGO – ResMed has reported revenues of $556.7 million for the fourth quarter ended June 30, a 7% increase over to the same period in 2016. Excluding contributions from Brightree, revenues were $520.5 million, a 6% increase.

CPAP systems evolve to meet demand

 - 
05/23/2017

Greater public awareness of obstructive sleep apnea, ongoing technological advancements and stronger patient compliance are all contributing factors in the continued viability of the sleep therapy industry, market specialists say.

ResMed studies connect the dots on central sleep apnea

 - 
05/23/2017

SAN DIEGO – People with treatment-emergent central sleep apnea (CSA) have a significantly greater risk of terminating CPAP therapy, according to a new ResMed-sponsored study presented on May 22 at the 2017 American Thoracic Society International Conference.

Legal wrangle: ResMed withdraws complaint, plans to refile

 - 
05/18/2017

SAN DIEGO – ResMed has filed a motion to dismiss a complaint against Fisher & Paykel so that it can refile using new evidence it has gathered that will it a give stronger case, according to a press release.

Pages